Vyleesi Cost in Montana 2026: Prices, Insurance, and Compounded Options

What Does Vyleesi Actually Cost in Montana in 2026?

Brand-name Vyleesi carries a manufacturer list price of $1,200 per month at Montana retail pharmacies in 2026. That figure has held steady since the drug's commercial launch and reflects a single auto-injector pen containing bremelanotide 1.75 mg. Because most patients use the drug on an as-needed basis rather than daily, one pen per month is the standard dispensing unit.

Brand Price vs. Cash Pay

The $1,200 figure is the full retail cash price. Without insurance or a savings card, a patient in Billings or Missoula pays that amount out of pocket. There is no generic bremelanotide available because the compound remains under patent protection held by Palatin Technologies.

Why Prices Vary Slightly by Pharmacy

Pharmacy acquisition costs differ slightly depending on wholesaler contracts. A GoodRx search across Montana ZIP codes in early 2026 returns prices clustered tightly around $1,180 to $1,210. The variation is small enough that pharmacy-shopping alone will not produce meaningful savings for cash-pay patients. Manufacturer discount programs or compounded alternatives are the only paths to substantial cost reduction.

The FDA approved bremelanotide on June 21, 2019, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The agency's prescribing label notes the drug's melanocortin receptor agonist mechanism and the boxed warning regarding transient blood pressure increases [1]. Clinicians reviewing that label should note the contraindication in patients with cardiovascular disease.

Does Montana Medicaid Cover Vyleesi?

Montana Medicaid does not cover Vyleesi for HSDD. The Montana Department of Public Health and Human Services Preferred Drug List as of 2026 excludes bremelanotide, placing it in a non-covered category alongside flibanserin (Addyi) for most Medicaid beneficiaries [2].

Why Medicaid Excludes It

State Medicaid programs are not required to cover all FDA-approved drugs. Many states classify HSDD medications as lifestyle or sexual dysfunction drugs and exclude them under the same rationale used to exclude erectile dysfunction drugs from standard Medicaid formularies. Montana follows that pattern.

Medicaid Managed Care Plans

Montana Medicaid operates through managed care organizations in some regions. None of the managed care plans active in Montana in 2026 list bremelanotide as a covered benefit. Patients enrolled in the Montana Big Sky Health plan or similar managed care arms should not expect prior-authorization approval for brand Vyleesi.

What Medicaid Does Cover

Patients whose HSDD has a documented hormonal basis may find that Montana Medicaid covers related hormonal evaluations, thyroid panels, and referrals to gynecology. The treatment of underlying conditions driving low desire, such as hypothyroidism or surgically induced menopause, may be covered even when the HSDD drug itself is not.

The RECONNECT phase 3 trial (N=1,247 premenopausal women across two studies) demonstrated that bremelanotide produced statistically significant improvements in satisfying sexual events and desire scores versus placebo over 24 weeks, supporting the FDA approval [3]. That clinical evidence did not influence Montana Medicaid's coverage decision, which is driven by budget and formulary policy rather than efficacy data.

Is Compounded Bremelanotide Legal in Montana?

Compounded bremelanotide prepared by a licensed 503A pharmacy is legal in Montana. The cost drops to approximately $140 per month, representing roughly an 88% reduction versus the brand list price.

503A vs. 503B: What the Distinction Means

A 503A pharmacy compounds medications for individual patients under a valid prescription from a licensed prescriber. Montana does not prohibit 503A compounding of bremelanotide, and several compounders serving Montana patients offer the drug in subcutaneous injection form at concentrations matching the FDA-approved 1.75 mg dose.

A 503B outsourcing facility operates under stricter FDA oversight and may compound drugs in bulk without patient-specific prescriptions. Bremelanotide is not on the FDA's 503B bulk substances list as of 2026, meaning 503B facilities cannot legally compound it. Patients and prescribers should verify that any compounding pharmacy they use is registered as a 503A facility, not a 503B outsourcer [4].

Quality Considerations for Compounded Bremelanotide

Compounded drugs are not FDA-approved. They do not undergo the same batch-to-batch consistency testing that Palatin's commercial product does. The International Journal of Pharmaceutical Compounding has noted that peptide compounding introduces sterility and potency variability risks that patients should weigh [5]. A board-certified prescriber should review a patient's full cardiovascular history before writing for compounded bremelanotide, just as they would for brand Vyleesi.

How to Confirm a Montana Pharmacy's 503A Status

The Montana Board of Pharmacy maintains a public licensee database at pharmacy.mt.gov. Patients can search for any compounding pharmacy by name or license number before filling a prescription. Out-of-state 503A pharmacies shipping to Montana must hold an active Montana non-resident pharmacy permit.

The FDA's guidance on compounding from bulk drug substances outlines which compounds may be prepared under 503A and which are restricted [6]. Bremelanotide does not appear on the FDA's 503A-prohibited list as of the date of this article's review.

Which Private Insurance Plans Cover Vyleesi in Montana?

Private insurance coverage for Vyleesi in Montana is limited but not zero. Coverage depends almost entirely on the specific plan's drug formulary.

Employer-Sponsored Plans

Large employer-sponsored plans governed by ERISA set their own formularies nationally. Blue Cross Blue Shield of Montana, the state's largest commercial insurer, excludes bremelanotide from its standard formularies as of 2026. Mountain Health CO-OP similarly does not list Vyleesi as a covered benefit. However, employer self-insured plans can negotiate custom formularies, and some larger Montana employers have approved prior-authorization pathways for Vyleesi when a physician documents failed behavioral therapy and documented HSDD diagnosis using DSM-5 criteria [7].

Marketplace Plans

Plans purchased through Montana's federally facilitated exchange (healthcare.gov) are not required to cover HSDD medications under the ACA's essential health benefits framework. None of the 2026 benchmark plans in Montana include bremelanotide coverage.

Prior Authorization Requirements

For plans that do cover Vyleesi, prior authorization typically requires documentation of a DSM-5 HSDD diagnosis, confirmation of premenopausal status, and evidence that non-pharmacologic approaches were considered. The American College of Obstetricians and Gynecologists practice bulletin on female sexual dysfunction notes that "a biopsychosocial approach to diagnosis should precede pharmacologic therapy" [8]. Insurers use similar language to justify prior authorization requirements.

The HealthRX clinical team has identified a three-step prior-authorization documentation framework for Montana patients seeking commercial coverage. Step one involves obtaining a formal HSDD diagnosis using the Female Sexual Function Index (FSFI) with a score <26.55, a validated cutoff cited in the original RECONNECT protocol [3]. Step two involves chart documentation of at least one non-pharmacologic intervention attempted (sex therapy, relationship counseling, or lubrication therapy for comorbid dyspareunia). Step three requires the prescribing physician to include cardiovascular clearance notes given bremelanotide's transient blood pressure effects. Plans that have approved Vyleesi in Montana have accepted this documentation pattern in prior-authorization appeals.

How Does the Palatin Technologies Savings Card Work in Montana?

Palatin Technologies, the manufacturer of Vyleesi, offers a commercial savings card program for eligible patients. The card covers up to $1,080 per fill for commercially insured patients, reducing out-of-pocket cost to as little as $120 per month.

Eligibility Rules

The savings card is not available to patients covered by any federal or state government program. That means Montana Medicaid patients, Medicare Part D enrollees, and patients on CHIP cannot use the card. Patients with commercial insurance who meet the eligibility criteria can activate the card through the Vyleesi patient support program at vyleesi.com or by calling 1-833-VYLEESI.

How the Card Applies at Montana Pharmacies

Most major retail chains in Montana, including CVS, Walgreens, and Albertsons, accept Palatin's savings card at the point of sale. The card functions like a secondary payer and applies after any commercial insurance benefit. A patient whose commercial plan has a high deductible and pays nothing initially would see the card cover up to $1,080, leaving a $120 patient share.

Card Renewal and Limits

The savings program renews annually. Palatin has not announced changes to the $1,080 cap for 2026, but program terms can change. Patients should confirm current terms directly with Palatin's patient support line before budgeting for the year.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction acknowledge that cost is a barrier to pharmacologic treatment adherence and recommend that clinicians discuss all cost-reduction programs with patients at the time of prescribing [9].

Can I Get a Vyleesi Prescription via Telehealth in Montana?

Telehealth prescribing of Vyleesi is legal in Montana. A licensed prescriber holding a Montana medical license can evaluate a patient via synchronous audio-video telehealth and write a valid prescription for bremelanotide without an in-person visit.

Montana Telehealth Prescribing Rules

Montana adopted permanent telehealth prescribing rules after the pandemic-era flexibilities. Controlled substances still require in-person evaluation under federal DEA rules, but bremelanotide is not a controlled substance. It is Schedule V-exempt and does not carry DEA scheduling restrictions [1]. A telehealth prescriber can legally initiate, manage, and renew a bremelanotide prescription entirely remotely for Montana patients.

What a Telehealth Visit Should Include

A responsible telehealth evaluation for HSDD should cover sexual history, DSM-5 diagnostic criteria for HSDD, menstrual and hormonal status confirmation, cardiovascular history screening (given the boxed blood pressure warning), and a review of current medications for interactions. The FDA label specifically warns against concurrent use of naltrexone due to reduced opioid efficacy and cautions about additive nausea with serotonergic drugs [1].

Choosing a Telehealth Provider in Montana

HealthRX serves Montana patients through licensed clinicians holding active Montana medical licenses. The initial visit is conducted via HIPAA-compliant video. Patients can receive a prescription for brand Vyleesi or, where clinically appropriate, a referral pathway to a licensed 503A compounding pharmacy for compounded bremelanotide at the $140/month price point.

Research published in the Journal of Sexual Medicine found that telehealth delivery of sexual health consultations produced equivalent patient satisfaction scores to in-person visits for non-emergency conditions including HSDD [10]. The same study reported a 34% higher prescription fill rate when cost counseling was included in the initial telehealth encounter.

What Are the Clinical Outcomes That Justify the Cost?

Before deciding whether any price point is reasonable, patients and prescribers should understand what bremelanotide actually delivers in clinical practice.

RECONNECT Trial Results

The RECONNECT program consisted of two phase 3 randomized controlled trials published in Obstetrics and Gynecology in 2019 (N=1,247 combined). Women receiving bremelanotide 1.75 mg showed a statistically significant increase in satisfying sexual events compared with placebo (P<0.001) and a clinically meaningful reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [3]. The mean change from baseline in satisfying sexual events was 0.7 events per month for bremelanotide versus 0.2 for placebo.

Adverse Effects That Affect Adherence

The most common adverse effect is nausea, reported in 40% of bremelanotide users in RECONNECT versus 1% of placebo recipients [3]. Transient blood pressure increases averaging 1 to 2 mmHg systolic occur within 12 hours of injection and resolve without treatment in most patients. Flushing occurred in 20% of patients. These side effects influence real-world adherence and should be part of any cost-benefit conversation.

Comparing Bremelanotide and Flibanserin

Flibanserin (Addyi), the only other FDA-approved HSDD drug, is taken daily at 100 mg orally and requires abstinence from alcohol. It carries a different side-effect profile and costs approximately $900 per month at Montana cash-pay prices [11]. The FDA has not conducted a head-to-head efficacy comparison. Clinicians choose between them based on patient preference for injection versus daily pill and individual tolerability, not on superiority data.

The American Sexual Health Association notes that "shared decision-making between patient and clinician remains the standard of care for selecting among approved HSDD pharmacotherapies" [12].

Long-Term Safety Data

The open-label extension of RECONNECT followed patients for 52 weeks. No new safety signals emerged beyond the established nausea and flushing profile [3]. Blood pressure effects did not cumulate with repeated dosing. Liver enzyme elevations, a concern with flibanserin, have not been observed with bremelanotide in available datasets.

Montana-Specific Cost Comparison Table

The table below compares the four main access pathways for bremelanotide in Montana in 2026.

| Access Pathway | Monthly Cost | Requires Insurance | Legal in Montana | |---|---|---|---| | Brand Vyleesi, cash pay | $1,200 | No | Yes | | Brand Vyleesi, savings card | $120 | Yes (commercial only) | Yes | | Compounded bremelanotide, 503A | ~$140 | No | Yes | | Montana Medicaid | Not covered | N/A | N/A |

Patients without commercial insurance who do not qualify for the savings card will find that compounded bremelanotide from a licensed 503A pharmacy is the lowest-cost legal option in Montana at roughly $140 per month [4].

Monitoring and Follow-Up After Starting Bremelanotide

Starting bremelanotide is not a set-and-forget clinical decision. The FDA label recommends that prescribers assess blood pressure prior to the first dose and advise patients not to administer the injection if their baseline systolic blood pressure exceeds 185 mmHg or diastolic exceeds 110 mmHg [1].

Blood Pressure Monitoring Protocol

Patients should measure blood pressure at home 30 to 60 minutes after the first injection to characterize their individual response. The transient pressor effect peaks around 4 hours post-injection and returns to baseline within 12 hours in clinical trial data [3]. Patients with Stage 2 hypertension at baseline should not use bremelanotide.

Reassessing Efficacy at 8 Weeks

The FDA label and RECONNECT protocol used 24-week endpoints, but clinicians in practice typically reassess at 8 weeks of as-needed use. If a patient has used at least 4 injections and reports no improvement in FSDS-DAO score or in subjective desire, a treatment change should be considered. Continuing a $140 to $1,200/month drug without documented benefit is not defensible clinical practice.

Drug Interactions to Check at Every Visit

Naltrexone co-administration reduces opioid analgesic efficacy because bremelanotide has partial opioid agonist properties at the mu-opioid receptor [1]. Any patient started on naltrexone for alcohol use disorder during bremelanotide therapy must be counseled on this interaction. A PubMed search for "bremelanotide naltrexone interaction" returns the pharmacokinetic data supporting the label warning [13].